Molecular monitoring of responses to DLI and DLI + IFN treatment of post-SCT relapses in patients with CML

Leukemia Research

Volumn 27, Issue 8, 2003, Pages 719-729

  Moravcová, Jana ^a   Nádvorníková, Sylvie ^a   Zmeková, Václava ^a   Michalová, Kyra ^a   Březinová, Jana ^a   Lukášová, Marcela ^a   Vítek, Antonín ^a   Hrabánek, Jan ^a   Gašová, Zdenka ^a   Sedláček, Petr ^b   Starý, Jan ^b  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

BCR ABL monitoring; CML; DLI, DLI + IFN; Quantitative RT PCR; Relapse; Stem cell transplantation

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN;

ACCURACY; ADULT; ARTICLE; BLAST CELL CRISIS; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LEUKEMIA REMISSION; LYMPHOCYTE TRANSFUSION; MALE; PATIENT MONITORING; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SURVIVAL TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; CHILD; COMBINED MODALITY THERAPY; FEMALE; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTERFERON-ALPHA; LEUKEMIA, MYELOID, CHRONIC; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS;

EID: 0037528760     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00280-1     Document Type: Article

References (34)

1. Lion T., Izraeli S., Henn T., Gaiger A., Mor W., Gadner H. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction. Leukemia. 6:1992;495.
2. Cross N.C.P., Feng L., Chase A., Bungey J., Hughes T.P., Goldman J.M. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood. 82:1993;1929.
3. Moravcová J., Lukášová M., Starý J., Haškovec C. Simple competitive two-step RT-PCR assay to monitor minimal residual disease in CML patients after bone marrow transplantation. Leukemia. 12:1998;1303.
4. Emig M., Saussele S., Wittor H., Weisse A., Reiter A., Willer A.et al. Accurate and rapid analysis of residual disease in patients with CML using specific fluorescent hybridization probes for real-time quantitative RT-PCR. Leukemia. 13:1999;1825.
5. Lion T., Henn T., Gaiger A., Kalhs P., Gadner H. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukemia. Lancet. 341:1993;275.
6. Lion T. Clinical implications of qualitative and quantitative polymerase chain reaction analysis in the monitoring of patients with chronic myelogenous leukemia. Bone Marrow Transplant. 14:1994;505.
7. Lin F., van Rhee F., Goldman J.M., Cross N.C.P. Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood. 87:1996;4473.
8. Goldman JM. Stem cell transplantation for CML: its place in treatment algorithms. Education Program Book: 43rd ASH Annual Meeting, Orlando, FL, December 7-11, 2001. p. 103.
9. Kolb H.J., Mittermüller J., Clemm C.H., Holler E., Ledderose G., Brehm G.et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 76:1990;2462.
10. Kolb H.J., Schattenberg A., Goldman J.M., Hertenstein B., Jacobsen N., Arcese W.et al. Graft-versus-leukaemia effect of donor lymphocyte transfusion in marrow grafted patients. Blood. 86:1995;2041.
11. Collins R.H., Shpilberg O., Drobyski W.R., Porter D.L., Giralt S., Champlin R.et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J. Clin. Oncol. 15:1997;433.
12. Raanani P., Dazzi F., Sohal J., Szydlo R.M., van Rhee F., Reiter A.et al. The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br. J. Haematol. 99:1997;945.
13. van Rhee F., Lin F., Cullis J.O., Spencer A., Cross N.C.P., Chase A.et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of hematological relapse. Blood. 83:1994;3377.
14. van Rhee F., Savage D., Blackwell J., Orchard K., Dazzi F., Lin F.et al. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors. Bone Marrow Transplant. 21:1998;1055.
15. Mackinnon S., Papadopoulos E.B., Carabasi M.H., Reich L., Collins N.H., Boulad F.et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 86:1995;1261.
16. Slavin S., Naparstek E., Nagler A., Ackerstein A., Samuel S., Kapelushnik J.et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood. 87:1996;2195.
17. Dazzi F., Szydlo R.M., Craddock C., Cross N.C.P., Kaeda J., Chase A.et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood. 95:2000;67.
18. Keil F., Haas O.A., Fritsch G., Kalhs P., Lechner K., Mannhalter C.et al. Donor leukocyte infusion for leukaemiac relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood. 89:1997;3113.
19. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156.
20. Moravcová J., Nádvorníková S., Březinová J. Overproduction of BCR-ABL transcripts in human leukemic cell lines K562 and BV173. Eur. J. Haematol. 64:2000;135.
21. Moravcová J., Muchová S., Kalbáčová R., Haškovec C. Single-tube quantitative RT-PCR for monitoring of the response to IFN treatment in CML patients. Leukemia. 12:1998;1326.
22. Kolb JH. Donor lymphocyte transfusion for the treatment of chronic myelogenous leukemia. Abstract Book: ESH Conference on Chronic Myeloid Leukemia, Rapallo, Portofino, Italy, September 22-25, 2000.
23. Mehta J., Powles R., Kulkarni S., Cross N.C.P., Kaeda J., Chase A. Induction of graft-versus-host disease as immunotherapy of leukemia relapsing after allogeneic transplantation: single-center experience of 32 adult patients. Bone Marrow Transplant. 20:1997;129.
24. Serrano J., Prieto E., Mazarbeitia F., Román A., Llamas P., Tomás J.F. Atypical chronic graft-versus-host disease following interferon therapy for chronic myeloid leukemia relapsing after allogeneic BMT. Bone Marrow Transplant. 27:2001;85.
25. Higano C.S., Chielens D., Raskind W., Bryant E., Flowers M.E., Radich J.et al. Use of alpha-2a-interferon to treat cytogenetic relapse of chronic myeloid leukemia after marrow transplantation. Blood. 90:1997;2549.
26. Steegmann J.L., Casado L.F., Tomas J.F., Sanz-Rodriguez C., Granados E., de-la-Camara R.et al. Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation. Bone Marrow Transplant. 23:1999;483.
27. Slavin S., Naparstek E., Nagler A., Ackerstein A., Kapelushnik J., Or R. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral lymphocytes. Exp. Hematol. 23:1995;1553.
28. Schmidt H., Kellermann-Kegreiss E., Steiert I., Walz J., Zinser R., Muller C.A. Differential regulation of human leukocyte antigen class I genes by interferon in vivo and in vitro. J. Immunother. 14:1993;169.
29. Shlomchik W.D., Emerson S.G. The immunobiology of T cell therapies for leukemias. Acta Hematol. 96:1996;189.
30. Oka T., Sastry K.J., Nehete P., Schapiro S.J., Guo J.Q., Talpaz M.et al. Evidence for specific immune response against P210 BCR-ABL in long-term remission CML patients treated with interferon. Leukemia. 12:1998;155.
31. Chen X., Regn S., Raffegerst S., Kolb H.J., Roskrow M. Interferon alpha in combination with GM-CSF induces the differentiation of leukemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukemic cytotoxic T-cell response from patients with chronic myeloid leukaemia. Br. J. Haematol. 111:2000;596.
32. Selleri C., Sato T., Del-Vecchio L., Luciano L., Barrett A.J., Rotoli B. Involvement of FAS-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood. 89:1997;957.
33. Selleri C., Maciejewski J.P., Pane F., Luciano L., Raiola A.M., Mostarda I.et al. FAS-mediated modulation of BCR/ABL in chronic myelogenous leukemia results in differential effects on apoptosis. Blood. 92:1998;981.
34. Dazzi F., Szydlo R.M., Cross N.C.P., Craddock C., Kaeda J., Kanfer E. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 96:2000;2712.